JyotiPatelMDFASCO

Oncology • Chicago, IL

Professor in Medicine-Hematology/Oncology, Northwestern University Medical School

Join to view full profile

Dr. Patel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Patel's full profile

Already have an account?

Office
676 N. St. Clair
Suite 850
Chicago, IL 60610
Phone+1 312-695-6180

Fax+1 312-695-0990

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2000 - 2003
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1996 - 2000
Indiana University School of MedicineClass of 1996

Certifications & Licensure

IL State Medical License 1998 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Fellow of the American Society of Clinical Oncology American Society of Clinical Oncology, 2018
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer Start of enrollment: 2008 Jan 01
Completed
Phase 2
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer Start of enrollment: 2013 Feb 01
Terminated
Phase 2, Phase 3
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
No longer available
CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer Start of enrollment: 2021 Mar 10
Active, not recruiting
Phase 2
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2022 Apr 14
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator
A Study of EP0031 in Patients With Advanced RET-altered Malignancies Start of enrollment: 2022 Sep 30
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemo...
Sai-Hong Ignatius Ou, Thibaud Prawitz, Huamao M Lin, Jin-Liern Hong, Min Tan
Clinical Lung Cancer. 2024-05-01
Addition of Trastuzumab Deruxtecan to Selpercatinib in a Patient With RET Fusion-Driven NSCLC and an Acquired HER2 Amplification: Case Report.
Chetan V Vakkalagadda, Jyoti D Patel
JTO Clinical and Research Reports. 2023-12-01
Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Har...
J Nicholas Bodor, Jyoti D Patel, Heather A Wakelee, Benjamin P Levy, Hossein Borghaei
Clinical Lung Cancer. 2023-11-01

Press Mentions

Immunotherapy May Soon Be First-Line Tx for Advanced NSCLCJuly 2nd, 2016
E-cigarette Users Often Believe Devices Will Help Them Quit Tobacco - US NewsJune 4th, 2015
Cancer Study Could Change Radiation Treatment for Hundreds of ThousandsMay 31st, 2015
Join now to see all